MedTrace Logo

ROMEO (Rosuvastatin in Metabolic syndrOme)

NCT00395486 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 258

Last updated 2011-07-11

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to compare the effect of rosuvastatin 10mg with atorvastatin 10mg after 6 weeks of treatment in the ratio of ApoB/ApoA1 in subjects with metabolic syndrome.

Conditions

  • Metabolic Syndrome X

Interventions

DRUG

Rosuvastatin

10mg

DRUG

Atorvastatin

10mg

Sponsors & Collaborators

Principal Investigators

  • JoonWoo Bahn, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00395486 on ClinicalTrials.gov